Aurobindo Pharma Ltd, a Rs 3,000 crore Hyderabad based pharma giant, has established AuroSource, a service oriented and customer-centric division with in the company. The new division will provide custom R&D and manufacturing (CRAMS) services for large, mid-sized and emerging biotech and pharmaceutical entities globally.
AuroSource will partner with these companies and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle. It will provide fully consolidated or customized manufacturing solutions for APIs, intermediates, pre-formulations and formulations across each stage of he pharmaceutical life cycle. It will also provide regulatory, research and development expertise from the pre-clinical stage through the post patent expiry phase in drug development.
Ramprasad Reddy, chairman, said, “AuroSource is uniquely positioned to smoothly transition our competence in drug development to customers within this market segment. We stand to become an invaluable partner in enabling them to streamline and simplify their development and manufacturing processes so they can focus primarily on creating life-saving, low-cost products and contribute to making global healthcare more affordable.”
AuroSource officials recognize that this is a critical time to enter this market. Impending reforms in the US healthcare market have exposed a need for contract manufacturing services. The AuroSource team organized from the parent company has commercialized more than 200 APIs and 120 finished drug products.